Your new experience awaits. Try the new design now and help us make it even better

MINI REVIEW article

Front. Pharmacol.

Sec. Drugs Outcomes Research and Policies

Volume 16 - 2025 | doi: 10.3389/fphar.2025.1681815

This article is part of the Research TopicCannabidiol: Perspectives on Drug-Resistant Epilepsy ManagementView all articles

Practical approach to the safe use of cannabidiol in patients with refractory epilepsy: A mini review

Provisionally accepted
  • University of Antioquia, Medellín, Colombia

The final, formatted version of the article will be published soon.

Drug-resistant epilepsy (DRE), characterized by seizures that are unresponsive to the use of two or more conventional anti-seizure medication (ASMs), poses a significant therapeutic challenge. In recent years, cannabidiol (CBD), a non-psychoactive compound derived from Cannabis sativa, has emerged as a promising adjunctive therapy for specific, severe epilepsy syndromes. The approval of a highly purified 99% CBD oral solution (Epidiolex®) has facilitated its integration into clinical practice. However, its effective and safe use requires a nuanced understanding of several practical considerations. This narrative review synthesizes current evidence on the practical aspects of prescribing and administering highly purified CBD oral solution in patients with drug-resistant epilepsy (DRE). I address evidence-based dosing strategies, relevant drug-drug interactions, the profile of adverse-drug reactions (ADRs) and their management, and the critical importance of gradual dose titration. A comprehensive literature search was conducted to identify relevant clinical trials, systematic reviews, observational studies, real-world evidence, and other pertinent publications. A "start low, go slow" dosing approach is essential to mitigate ADRs, which are generally mild to moderate but may include somnolence, decreased appetite, diarrhea, and, most notably, elevated liver transaminases, particularly with concurrent valproate use. Significant pharmacokinetic interactions, especially with clobazam, require careful monitoring and potential dose adjustments of concomitant ASMs. This review offers a consolidated overview of the practical considerations for CBD therapy, aiming to support clinicians in optimizing treatment outcomes for patients with DRE while ensuring patient safety.

Keywords: Cannabidiol, Cannabis, Drug-resistant epilepsy, Epilepsy, Seizures

Received: 07 Aug 2025; Accepted: 25 Aug 2025.

Copyright: © 2025 Navarro. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Cristian Eduardo Navarro, University of Antioquia, Medellín, Colombia

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.